Registered in 5 countries, being reviewed in major countries and preparing for registration
Ensures the possibility that the Hybrozyme™ platform technology will be expanded in different directions in the future
(Photo = Alteogen)
[바이오타임즈] Alteogen, a bio-platform company, announced that its patent office has completed domestic patent registration for a mixed formulation of ALT-B4, a variant of human hyaluronidase PH20, and various medicines such as antibody drugs, low molecular weight compounds, aptamers, and RNAi Published on the 29th.
Alteogen has continuously worked to protect its intellectual property rights and expand the unique position of its Hybrozyme™ platform technology. This patent is one of those efforts, and the claims with extended rights have been acknowledged.
By registering this invention, which is claimed by various types of medicines, including antibodies, which are existing or potential therapeutic candidate substances, Alteogen has secured the possibility that the Hybrozyme™ platform technology will be expanded in various areas in the future. This patent has been registered in five countries so far, and is being prepared for registration after review in major countries where applications are filed.
An Alteogen official explained, “In order to smoothly collaborate with antibody treatment developers, we have established a stable intellectual property portfolio by acquiring patents that can guarantee exclusive rights in advance.”
He continued, “While we are working to expand the Hybrozyme™ platform, including subcutaneous ADC treatments, we understand that various efforts are being made overseas, such as subcutaneous formulations of cell therapy.” He added, “Through this invention, we collaborate with these efforts “We will be able to secure intellectual property rights to expand the application of the platform and even extend the patent rights,” he expressed his expectations.
The Hybrozyme™ platform is a technology independently developed by Alteogen to convert intravenous drugs into subcutaneous formulations. To date, the technology has been exported to a total of four companies, including MSD, Intas, and Sandoz, two of which are undergoing clinical trials for product approval.
The company has a solid patent strategy, such as this patent, and aims to continuously export the platform technology by proving the technology through clinical success and commercializing items using the platform technology.
Meanwhile, Alteogen is a company that develops and provides bio platforms. We are developing a platform for long-acting biobeters, an antibody-drug combination platform, and a platform for converting intravenous drugs into subcutaneous formulations, and we are using these to export technology and develop products.
Starting with Tergase®, a stand-alone recombinant hyaluronidase product expected to be approved and marketed this year, the in-house developed products and products applied to the ALT-L2 and Hybrozyme™ platforms, a technology that has was exported to foreign pharmaceutical companies, became visible.
[바이오타임즈=김수진 기자] sjkimcap@biotimes.co.kr
Copyright © BioTimes Reproduction and redistribution prohibited.
#Alteogen #completes #domestic #patent #registration #formulation #formulation #drug #combination
